These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 36847998)

  • 61. Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
    Zalacain M; Lozano C; Llanos A; Sprynski N; Valmont T; De Piano C; Davies D; Leiris S; Sable C; Ledoux A; Morrissey I; Lemonnier M; Everett M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820763
    [TBL] [Abstract][Full Text] [Related]  

  • 62.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
    Petty LA; Henig O; Patel TS; Pogue JM; Kaye KS
    Infect Drug Resist; 2018; 11():1461-1472. PubMed ID: 30254477
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinical experience using cefiderocol].
    Witzke O; Brenner T
    Med Klin Intensivmed Notfmed; 2023 Mar; 118(2):149-155. PubMed ID: 35913604
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    Adams J; Santarossa M; Harrington A; Bauer M; Wozniak A; Labuszewski L; Albarillo FS
    Infect Dis (Lond); 2023 Apr; 55(4):282-291. PubMed ID: 36772806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
    Nurjadi D; Kocer K; Chanthalangsy Q; Klein S; Heeg K; Boutin S
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0201121. PubMed ID: 34871093
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS; Gould IM; Lee WS; Hsueh PR;
    Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy.
    Stracquadanio S; Torti E; Longshaw C; Henriksen AS; Stefani S
    J Glob Antimicrob Resist; 2021 Jun; 25():390-398. PubMed ID: 34020073
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
    Shen S; Tang C; Ding L; Han R; Yin D; Yang W; Guo Y; Hu F
    mSphere; 2022 Dec; 7(6):e0048722. PubMed ID: 36374086
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.
    Tompkins K; van Duin D
    Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2053-2068. PubMed ID: 34169446
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
    Ong'uti S; Czech M; Robilotti E; Holubar M
    Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
    Thelen P; Henriksen AS; Longshaw C; Yamano Y; Caldwell B; Hamprecht A
    J Glob Antimicrob Resist; 2022 Mar; 28():12-17. PubMed ID: 34920174
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
    Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
    Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
    [TBL] [Abstract][Full Text] [Related]  

  • 80. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.